In short
Clinical trials are studying Alks 2680 in people with idiopathic hypersomnia and narcolepsy. These studies look at safety, effectiveness, and long-term tolerability in adults with excessive daytime sleepiness. They include Phase 2 and Phase 4 trials with different dose levels and placebo comparisons.
Key points
- Clinical trials of Alks 2680 are studying people with idiopathic hypersomnia and narcolepsy type 1 or type 2. The research includes Phase 2 studies and one Phase 4 long-term study. The main goals are to check whether the treatment helps with excessive daytime sleepiness and to assess safety and tolerability. Some trials compare different dose levels with placebo. The trials use measures such as the Epworth Sleepiness Scale, the Maintenance of Wakefulness Test, and treatment-emergent adverse events.
Clinical trial overview
Several interventional studies are investigating Alks 2680 in people with sleep disorders that cause strong daytime sleepiness. The studies include both short-term and long-term research, and they are designed to look at safety, effectiveness, and tolerability.
Conditions being studied
The trials focus on idiopathic hypersomnia, narcolepsy type 1, and narcolepsy type 2. Idiopathic hypersomnia means a person has severe sleepiness, but the cause is not known. Narcolepsy is another sleep disorder linked to excessive daytime sleepiness, and the trials separate type 1 and type 2 when needed.
Study designs, phases, and treatments
Three of the studies are Phase 2 trials, which are usually used to learn more about early effectiveness and safety. One study is a Phase 4 long-term trial, which is focused on safety and tolerability over time.
The idiopathic hypersomnia study includes Alks 2680 doses of 10 mg, 14 mg, and 18 mg, plus a placebo that matches the study drug. The narcolepsy type 2 study includes 10 mg, 14 mg, and 18 mg doses, also with placebo. The narcolepsy type 1 study includes 4 mg, 6 mg, and 8 mg doses, with placebo. The long-term study includes several oral dose levels, from 4 mg to 18 mg.
Who can participate
The study populations are people with the conditions named in each trial: idiopathic hypersomnia, narcolepsy type 1, or narcolepsy type 2. The source data does not give full join rules such as age limits or other medical requirements, so only the listed patient groups can be confirmed here.
Main outcomes measured
The trials mainly measure changes in sleepiness and safety-related outcomes. In the idiopathic hypersomnia and narcolepsy type 1 and 2 studies, the Epworth Sleepiness Scale (ESS) is used to track change from the start of the study to later weeks. The narcolepsy type 1 and type 2 studies also use the Maintenance of Wakefulness Test (MWT), which checks how well a person can stay awake in quiet conditions.
The long-term Phase 4 study measures treatment-emergent adverse events, meaning health problems that begin or get worse after treatment starts. This helps researchers understand longer-term safety and tolerability in a larger group of people.
What these trials are trying to show
Overall, the studies are trying to find out whether Alks 2680 can reduce excessive daytime sleepiness in people with idiopathic hypersomnia and narcolepsy. They also aim to show whether the treatment is safe enough for short-term use and how it performs during longer follow-up.